NBP CORPORATE PRESENTATION

The Company

2

Founded By Burrill & Company of United States Series A NewBridge Pharmaceuticals Ltd est. 2008 - A British Virgin Islands domicile

Co-investor Kuwait Life Sciences Co (KLSC) of National Technology Enterprises Co of

Kuwait (NTEC) – subsidiary of Kuwait Investment Authority Series B

NewBridge Pharmaceuticals FZ-LLC Corporate HQ est. 2010 - Dubai

Co-investor Élan Pharmaceuticals Series C Capital Paid-In: ~$65M

2

NewBridge is a first in class, investor-backed specialty pharmaceutical company. Our full service business model is built to bring long-term commercial excellence to our partners, in alignment with their regional goals We are specialized in in-licensing, acquiring, registering and commercializing FDA and EMA approved therapeutics and diagnostics to address the unmet medical needs of diseases with high regional prevalence We build value for our licensed brands and offer our partners a professional one-stop-solution; one contract, one logistical process, and one in-market contact for a complex and multiple geographies in our territory

Who We Are And What We Do

3

“One-Stop-Solution” for the AfMET markets

Regional and international corporate

Pharma experience in building

efficient organizations and successful

brands

Team with Proven track record in

multiple functions of the Pharma

industry

Addressing immediate needs of the

medical community and regulatory

bodies in the region

Pharmacovigilance Reporting

Expansive distribution Network

Full logistical and financial solutions,

through management of demand

forecasts, regional shipments where

applicable, and packaging as needed

Manage billing cycles and

receivables

Value alignment with partner's

strategy and flexibility in partnership,

ethics and Integrity in all we do

Key stakeholder management to optimize the commercial value of assets licensed

Years of experience in Sales & Marketing in local and global markets

Dossier compilation, file submission across numerous MoH in the region

Managing inspection and review

procedures

Gain marketing, pricing and

reimbursement approval

Professional Team Full Regulatory Service Pharmacovigilance and

Medical Affairs Capabilities

Commercialization Logistics and Financial Solutions Partnership, Ethics, Integrity

4

5

•Back end Integration

•Regional Clinical trials

•Partner in Ph III clinical development

R&D

• Innovative Therapeutic

•MDx / POC Diagnostics

•Orphan Disease

Licensing •Front end

Integration

•Packaging & Specialty

Manufacturing

Corporate Strategic Vision

Joe Henein President & CEO

Leadership

30 years experience in Pharma Industry covering ME, EU & Global

Most recently VP & Managing Director of Wyeth in MENA

Successful turn around to one of the fastest growing affiliate in the company

Grew Revenues in MENA 6.5x from $75M in ‘04 to $465M in ’09 – Enbrel® / Prevenar®

Prior responsibilities at Wyeth included :

VP & TA Co-Chair - Global Commercial Head for Infectious Diseases – Tygacil® / Zosyn®

VP & TA Co-Chair – Women’s Health Care

Various commercial roles in ECE & MEA

Served in many global committees within Wyeth (Development Council; Development Strategy Board; European Council)

Served as Vice Chair for PhARMA MEA, and Chairman of Ethics Review Board

6

Victor Hebert Chairman

Joe Henein President & CEO NewBridge Pharmaceuticals

Steve Burrill CEO, Burrill & Company

Qais Marafi Vice Chairman & CEO at KLSC

Managing Director, Burrill & Company Chief Administrative Officer and Chief Legal Officer Former Chairman of Heller Erhman

With Global Strategic Experience in Building Companies and Alliances

Former VP & Managing Director ME/Africa Wyeth Pharmaceuticals Former VP & Therapeutic Area Head – Women Heath Care Former VP & Global Therapeutic Commercial Chair Infectious Diseases – Wyeth

CEO, Burrill & Company Director, Depomed (NASDAQ:DEPO), Targacept (NASDAQ:TRGT) Former Chairman, Pharmasset (NASDAQ: VRUS)

Chairman & CEO, Kuwaiti Life Science Company Assistant Vice President, National Technology Enterprises Co. (Wholly owned by KIA)

Hans-Peter Hasler Chief Operating Office Elan

Menghis Bairu MD Exec. VP & Chief Medical Officer Elan

Corporate

Counsel

Chief Operating Officer Elan Corp., plc. Consultant to biotech and pharmaceutical companies (M&A, strategy and

marketing) HPH Management GmbH Chief Operating Officer (COO), Biogen Idec Inc., USA.

EVP, Head of Global Development & Chief Medical Officer, Elan Corp., plc. Founder and President, International Medical Foundation, Inc. Former Executive Vice President & Head of Onclave Therapeutics, Onclave Therapeutics LTD

Board of Directors

Executive Management Team

Baher Massoud, M.D. Chief Medical Officer

20+ years experience as head of Medical and Clinical Affairs in MNC

Lilly, Wyeth, Pfizer

Vanessa Edmunds Vice President HR & Legal

12+ years experience in ME senior regional HR roles + 8 years in legal practice in the UK.

8+ years pharmaceutical industry experience with Wyeth, Pfizer and Baxter

G. Garrett Vygantas, M.D. Vice President BD & licensing

15+ years in Healthcare, Venture Capital, Entrepreneur

Burrill VC, Genentech/Roche, Cowen, U Penn, Georgetown

Khaled A. Tamim Finance Director

17+ years finance experience in multinational and regional companies

Abbott Laboratories, Pepsi, Siemens AG, Transmed, Unilever

Darein Hassan Director Regulatory, Quality & Gov’t Affairs

Alaa El Gamal Commercial Director ME

25+ years experience in Sales, Marketing & BD

Cyanamid -Wyeth, Valeant MENA

Azab Youssef Commercial Director Africa

20+ years experience in Sales and Marketing

Pfizer, Aventis, Wyeth, Parke-Davis and Kabi Vitrium

Ahmed Saeed Commercial Director Immunology

30+ years experience in Sales and Marketing

Sanofi Aventis, Pharmitalia Carlo Erba, EVA Cosmetics Labs

Ahmed Nawito Marketing Director

Rosie Khodeir Director Business Operation & Strategy

10+ years experience in Commercial Business Analysis, Financial Accounting and External Audit

Pfizer, Wyeth, Pepsi Co

15+ years experience in Sales and Marketing

AstraZeneca, Janssen Cilag, Abbott

12+ years regulatory affairs experience in multinational

Bayer, Wyeth, Pfizer, Danone

UAE (Regional HQs)

Current presence (Commercial) Kuwait, Bahrain, Qatar, UAE, Saudi Arabia, Egypt, Libya, Jordan, Lebanon Entry 2014/2015 Turkey, Sudan, Morocco, Algeria, Tunisia, Yemen, Oman, Iran, South Africa

NewBridge Footprint

Core Pharma Strategic Portfolio

CNS Oncology Immunology GI & Antibiotic

NBP Partners

Unique, one-stop solution as in-licensing partner of choice in the AfMET region

Provide multi-country access to the growing emerging AfMET markets with

established NBP presence in many localities

Experienced team with Big Pharma leading practices and established local

stakeholder networks

Blockbuster and innovative brands as foundation for portfolio

Oncology, Immunology, CNS, & GI

Track record of success in registration, commercialization and building strong brand

equity

Fully established distribution and logistic networks

Medical Affairs & fully dedicated Pharmacovigelence expertise

Compliance and Ethics codes strictly followed

NewBridge - Your Partner of Choice in AfMET

12

Thank You

NBP TEAM

14

AFMET MARKET OVERVIEW

NBP Access 7 out of 17 Pharmerging Markets

AfMET Pharmaceutical market clusters ~ B$ 45

GCC ex. SAUDI Bahrain Kuwait Oman Qatar UAE Yemen

LEVANT Iraq Jordan Lebanon Syria

NORTH AFRICA Algeria Libya Morocco Tunisia

OTHER AFRICA Angola Ethiopia Namibia Sudan Tanzania

Iran, 3.3 GCC ex Saudi, 2.74

Saudi Arabia, 3.81

Levant, 2.7

Egypt, 2.9

Turkey, 10.38

North Africa, 4.16

South Africa, 3.74

Other Africa, 3.31

Pakistan, 3.8

High Growth Rate will Prevail

Source: IMF Database

SENEGAL

GUINEA

ALGERIA

KENYA

NIGERIA

MOROCCO

COTE D’IVOIRE

MAURITANIA

GHANA

GABON

TUNISIA

CAMEROON

ANGOLA

D.R.C.

TANZANIA

SYRIA

LIBYA

MALI

SIERRA LEONE

LIBERIA

BURKINAFASO

NIGERCHAD

EGYPT

SUDAN

C.A.R.

UGANDA

ETHIOPIA

SOMALIA

ZAMBIA

NAMIBIA

BOTSWANA

SOUTHAFRICA

MADAGASCAR

MOZAMBIQUE

ZIMBABWE

SWAZILAND

LESOTHO

MALAWI

ERITREA

DJIBOUTI

IRAQIRAN

SAUDI ARABIA

KUWAIT

UAE

OMAN

QATAR BAHRAIN

YEMEN

RWANDA

BURUNDI

EQUATORIAL GUINEA

REPUBLIC OF THE CONGO

CABINDA (ANGOLA)

MAURITIUS

SEYCHELLES

Turkey

BENIN

TOGO

IsraelPalestine

LEBANON

JORDAN

Middle East, Turkey & Africa will remain one of the fastest growing regions in the world over the next few years

– Its growth is supported by Number of Levers: Growing Population and Life Expectancy Increasing Disease Burden Increased Literacy & Awareness Rising Income, Affordability and Willingness to

pay Significant government spending on healthcare Increased coverage and health insurance Opportunities from Sub-Optimal HC structures

AfMET consists of 50+ countries & 600+M inhabitants